Orientia tsutsugamushi is a bacterium that is the causative agent of scrub typhus, a disease that is endemic in many parts of Asia and the Western Pacific. The bacterium is transmitted to humans by infected mites, and the disease can cause a range of symptoms, including fever, headache, muscle aches, and rash.

One of the key components of Orientia tsutsugamushi is its cell surface antigen, which is a protein that is expressed on the surface of the bacterium and plays a crucial role in its interaction with host cells. The antigen is believed to be involved in the attachment of the bacterium to host cells, as well as in the evasion of the host immune system.

The application of Orientia tsutsugamushi cDNA and recombinant antigen for serodiagnosis of human scrub typhus is an important tool in the diagnosis and treatment of this potentially fatal infection. The cDNA and antigen can be used to detect the presence of antibodies to the disease, as well as to identify the strain of the bacteria causing the infection. This type of serodiagnosis has several advantages over traditional methods, including improved sensitivity, specificity, and cost-effectiveness. Additionally, the use of cDNA and recombinant antigen can help to reduce the time needed to obtain a diagnosis, as well as provide more accurate results for both laboratory and clinical settings.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.